JESSICA MCNEESE: Open Payments
NPI 1770927121 · RUSSELLVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$722 in 37 payments from 12 companies in 2025. Trend: 2023 $642 · 2024 $570 · 2025 $722
Food & beverage: $722
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $159 |
| Novo Nordisk Inc | 8 | $129 |
| Axsome Therapeutics, Inc. | 6 | $120 |
| ABBVIE INC. | 3 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Abbott Laboratories | 1 | $24 |
| Amgen Inc. | 1 | $17 |
| PFIZER INC. | 1 | $17 |
Products named: Auvelity, AIRSUPRA, Ozempic, CAPLYTA, VRAYLAR, BREZTRI, REXULTI, KEVEYIS.
Industry payments across AR — which companies pay providers there.
